Advertise on podcast: AML Hub

During the latest AML Hub Steering Committee Meeting on August 11, 2026, key opinion leaders met to discuss the role of combination strategies in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML). The meeting opened with a presentation by Gail J. Roboz, followed by a discussion featuring Agnieszka Wierzbowska, Charles Craddock, Jorge Sierra, Lars Bullinger, and Roland Walter. Roboz reviews the rationale for combination strategies in FLT3m AML and discusses updates presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 29 – June 2, 2026, Chicago, US, and the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE. She considers potential future directions for FLT3 inhibitor-based combination strategies, followed by a discussion focused on how best to translate high remission rates into durable disease control and long-term outcomes. The steering committee also explores how treatment strategies may need to be individualized according to patient fitness, molecular profile, treatment response, and access to available therapies. Intended for healthcare professionals. This educational resource is independently supported by Daiichi Sankyo. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

Steering committee meeting In August, 2026, the AML Hub held a steering committee meeting where Joshua Zeidner presented on Targeting menin: A paradigm shift in acute myeloid leukemia therapy, followed by a panel discussion. This podcast is independently supported by Kura Oncology. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far? Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, including how to select the most appropriate FLT3 inhibitor for different patient populations and how best to incorporate them into standard treatment regimens. He highlights the value of measurable residual disease (MRD) in monitoring disease status as an important insight from clinical trials. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML? Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML), including in combination regimens and in patients with FLT3-ITD-negative AML. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these? Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical trials: the phase III RATIFY (NCT00651261) trial, investigating the addition of midostaurin to standard chemotherapy in patients with newly diagnosed (ND) FLT3m AML; and the phase III QuANTUM-First (NCT02668653) trial, assessing the addition of quizartinib to standard chemotherapy in patients with ND FLT3-internal tandem duplication (FLT3-ITD) AML. He discusses data from trials aiming to further improve outcomes for patients with FLT3m AML and considers whether similar benefit can be demonstrated in patients requiring less intensive regimens. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The discussion featured contributions from Charles Craddock, Brian Huntly, and Jeffrey Lancet. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice? Roboz provides an overview of the key toxicities associated with menin inhibitor regimens in the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including differentiation syndrome, QT prolongation, and drug–drug interactions. She highlights the importance of recognizing these side effects as menin inhibitors move into routine clinical practice and shares how she approaches managing them. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies? Wang summarizes the rationale for menin inhibitor combination strategies for the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including their potential for improving outcomes and reducing the risk of on-target and off-target resistance vs menin inhibitor monotherapy. Wang also suggests mechanisms by which combination strategies might mitigate the risk of differentiation syndrome. Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care with FLT3 inhibitor therapy. The discussion featured contributions from Charles Craddock, Jorge Cortes, Hee-Je Kim, Jeffrey Lancet, Yasushi Miyazaki, Uwe Platzbecker, Roland Walter, and Agnieszka Wierzbowska. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? Zeidner provides an overview of currently approved menin inhibitors and discusses combination strategies in development for the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML). He highlights key data from ongoing trials of menin inhibitor combination approaches, which aim to improve outcomes in both newly diagnosed (ND) and relapsed/refractory (R/R) patient populations. This educational resource is independently supported Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with a panel Q&A discussion with live audience participation.  The panelists, Gail J. Roboz, Jorge Sierra, and Jorge Cortes, shared their perspectives on treatment decisions for patients with FLT3-mutated acute myeloid leukemia, including choice of FLT3 inhibitor, how FLT3-mutated measurable residual disease (MRD) might guide transplant decisions, as well as the importance of monitoring FLT3-mutated MRD with the appropriate assay.  This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) and FLT3-tyrosine kinase domain (TKD) mutations in clinical practice. Roboz reflected on whether 7+3 regimens are the most appropriate approach for older patients with FLT3-mutated AML, and reviewed considerations for using targeted FLT3 inhibitor therapies in combination with standard intensive chemotherapy. She then highlighted the importance of measurable residual disease (MRD) assessment in guiding treatment decisions before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the potential of triplet therapies for the treatment of patients with FLT3m AML. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the webinar by Jorge Cortes, Georgia Cancer Center, Augusta, US, discussing treatment options for patients with FLT3-ITD and -TKD mutations. Cortes describes the mechanisms of action of Type I and Type II FLT3 inhibitors, followed by an overview of key efficacy and survival data from clinical trials of FLT3-targeted therapies. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the presentations, by Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, discussing the types, prevalence, and clinical significance of FLT3 mutations in acute myeloid leukemia (AML). Sierra provided an overview of the role of FLT3-internal tandem duplication (ITD) and -tyrosine kinase domain (TKD) mutations in AML pathogenesis, and the differences in their molecular characteristics. He then discussed the prognostic value of FLT3-ITD and -TKD and concomitant mutations in patients with AML, and current risk stratification guidelines. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit patients with newly diagnosed acute myeloid leukemia (AML)? In this interview, Roboz discusses key findings from a preliminary subgroup analysis of a phase Ib/II trial (NCT04086264), investigating the anti-CD123 antibody–drug conjugate pivekimab sunirine in combination with azacitidine and venetoclax, for ≥14 days or 28 days, in unfit patients with newly diagnosed CD123-positive AML. The primary endpoint was antileukemic activity, including complete remission (CR) and composite CR with incomplete hematologic recovery (CR/CRi) rates. This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.